Evidence Table D3: DISCRETE outcomes for class ANTI-BACTERIAL (TOPICAL)/KERATOLYTIC (TOPICAL).

Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

D.01.01 Benzoyl peroxide Vehicle

Local reactions I Scaling 7

Stinging 1

Itching 3

Peeling 2

Scaling 3

Stinging 2

Itching 0

Peeling 3

Erythema 1

Burning 0

Soreness 0

Dryness 0

173

Parallel 

Mild/mod

N=77

È Mid (12)

Erythema 10

Burning 3

soreness 3

Dryness 5

Local reactions II Mid (12) Roughness 1 Roughness 1

Local effects Dryness, scaling, burning, stinging, 0.05

redness 22

None 22

Dryness, scaling, burning, stinging, 

redness 5

None 41

176

Parallel 

Mod/sev

N=150

Í

D.01.03 Benzoyl peroxide Gluconolactone

Local effects Dryness, scaling, burning, stinging, 0.05

redness 22

None 22

Dryness, scaling, burning, stinging, 

redness 11

None 34

176

Parallel 

Mod/sev

N=150

Í

D.01.09 Benzoyl peroxide (acetone) Benzoyl peroxide (alcohol)

Severity change Excellent 20 NS

Good 15

Fair 11

Poor 8

Excellent 11

Good 8

Fair 11

Poor 8

221

Parallel Mod

N=147

Í Mid (8)

D.05.01 Benzoyl peroxide + erythromycin Placebo

310 Side effects Scaling or tightness 14 Scaling or tightness 3 NS

Parallel 

Mild/mod

N=92

È Short (4)

Side effects

Between P-value: For scaling and burning

Mid (12) Scaling or tightness 13 Scaling or tightness 1 0.05

D.05.02 Erythromycin + benzoyl peroxide Clindamycin phosphate

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table D DISCRETE: Page 1 of 4

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Side effects Mild - moderate 3

Withdraw 3

Mild - moderate 1

Withdraw 0

260

Parallel 

Mild/mod

N=205

È Mid (10)

D.05.04 Benzoyl peroxide + erythromycin Zinc + erythromycin

Improved by 50% or more 62 Improved by 50% or more 22 Improved by 50% or more 8

Parallel Mod

N=72

Í Short (6)

Adverse effects Mid (10) Dryness/ irritation 1 Dryness/ irritation 4

Improved by 50% or more Mid (10) Improved by 50% or more 30 Improved by 50% or more 15

D.06.01 Meclocycline + benzoyl peroxide Benzoyl peroxide

Skin discoloration Present 1

Absent 32

Present 1

Absent 35

30

Parallel Mod

N=102

È Mid (10)

Benzoyl peroxide + 

metronidazole

D.07.01 Vehicle

Overall change/patient Much worse 0 0.05

Worse 0

Unchanged 1

Somewhat improved 3

Much worse 0

Worse 0

Unchanged 11

Somewhat improved 1

Improved 6

Much improved 2

121

Parallel 

Mod/sev

N=43

È Short (6)

Improved 4

Much improved 15

Overall change/patient 0-25% 3 0.05

26-50% 2

51-75% 6

76-100% 12

0-25% 9

26-50% 3

51-75% 8

76-100% 0

Short (6)

Severity change/photo 0-25% 2 0.05

26-50% 5

51-75% 5

76-100% 11

0-25% 10

26-50% 4

51-75% 6

76-100% 0

Short (6)

Benzoyl peroxide + 

metronidazole

D.07.02 Benzoyl peroxide

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table D DISCRETE: Page 2 of 4

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Overall change/patient Much worse 0 0.05

Worse 0

Unchanged 4

Somewhat improved 1

Much worse 0

Worse 0

Unchanged 8

Somewhat improved 4

Improved 4

Much improved 13

122

Parallel 

Mod/sev

N=60

È Short (6)

Improved 7

Much improved 18

Overall change/physician 0-25% 2 0.05

26-50% 2

51-75% 8

76-100% 18

0-25% 9

26-50% 3

51-75% 3

76-100% 14

Short (6)

Severity change/photo 0-25% 3 0.05

26-50% 4

51-75% 4

76-100% 19

0-25% 8

26-50% 2

51-75% 3

76-100% 16

Short (6)

D.08.01 Benzoyl peroxide + miconazole Benzoyl peroxide

Overall assessment/patient Excellent 7

Good 5

Moderate 1

None 1

Excellent 5

Good 6

Moderate 2

None 3

231

Parallel 

Mild/mod/sev

N=20

È Mid (8)

Overall assessment/physician Excellent 7

Good 4

Moderate 2

None 1

Excellent 7

Good 4

Moderate 2

None 3

Mid (8)

Side effects Present 3 NS

Absent 11

Present 2

Absent 14

Mid (8)

D.08.01 Miconazole + benzoyl peroxide Benzoyl peroxide

Severity change (score shift) -3 0 0.001

-2 0

-1 0

0 3

-3 0

-2 0

-1 1

0 12

+1 28

+2 9

+3 0

85

Parallel Mod

N=105

È Mid (8)

+1 26

+2 19

+3 1

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table D DISCRETE: Page 3 of 4

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Overall change/patient Excellent 28 0.001

Good 17

Moderate 5

Bad 1

Excellent 10

Good 17

Moderate 21

Bad 3

85

Parallel Mod

N=105

È Mid (12)

Overall change/physician Excellent 22 0.001

Good 21

Moderate 7

Bad 1

Excellent 8

Good 13

Moderate 23

Bad 7

Mid (12)

Severity change (score shift) -3 0 0.001

-2 0

-1 0

0 2

-3 0

-2 0

-1 2

0 8

+1 22

+2 16

+3 1

Mid (12)

+1 15

+2 26

+3 4

Side effects Irritation/dryness 1 0.005

Allergic reaction 0

None 50

Irritation/dryness 10

Allergic reaction 1

None 40

Mid (12)

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table D DISCRETE: Page 4 of 4

ÈÍ